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 Electrochemiluminescence platform for the detection of 
C-Reactive Protein : Application of recombinant 
antibody technology to cardiac biomarker detection  
(PPHW-2¶5HLOO\a,b, Paul J. Conroyb,c, Stephen Heartyb, Tia E. Keyesb, Richard 
2¶.HQQHG\b, Robert J. Forsterb, Lynn Dennanyc 
Abstract  
This work exploits the high-affinity of recombinant antibodies 
and low background electrochemiluminescence (ECL) for 
cardiac-biomarker detection. The developed assay is capable of 
fg mL-1 detection limits as well as the detection of C-Reactive 
Protein (CRP) over a clinically relevant range. The assay 
demonstrated robust reproducibility, selectivity and stability 
while also highlighting a novel platform for detection of cardiac 
biomarkers at low concentrations. 
Introduction 
 
Sensitive detection and accurate analysis of protein biomarker 
molecules are absolutely essential for the early detection, treatment 
and management of many diseases. In addition the recognition of 
disease biomarker patterns has a significant role to play in future 
disease prevention.[1, 2] Current approaches to biomarker detection 
typically involve ELISA or sandwich type immunoassays coupled 
with fluorescent or electrochemical detection. In addition 
electrochemiluminescence (ECL) based systems such as that 
developed by Roche have been commercialised and are currently 
used by clinicians worldwide for the detection of protein biomarkers. 
Sandwich-type immunoassays for biomarker detection typically 
employ a capture antibody immobilised on a surface that selectively 
enriches the concentration of target antigen at the sensor surface. A 
labeled secondary antibody then binds to the captured antigen and 
facilitates quantitative measurement of the analyte concentration. 
Common issues with ELISA based assays include sensitivity and 
specificity issues primarily caused by non-specific in addition to 
sub-optimal antibody orientation on the surface. In addition the 
challenges of immobilising heavy chain antibodies of approximately 
80 kDa to biosensor transduction platforms also persist. Recent 
advances in antibody engineering have enabled the development of 
low molecular weight single chain fragment variable (scFv) 
antibodies.[3, 4]. Primarily due to their reduced size and high 
specificity there has been much interest in 
 Scheme 1. Schematic illustration of the fabrication of recombinant 
antibody based biosensor for the detection of C-Reactive protein. 
The stepwise fabrication of the sensor is highlighted, scFv 
immobilization onto electrode or electrochemical probe, binding of 
pentameric CRP followed by binding of metal labeled ScFv 
fragments. 
 
scFv recombinant antibody technology and its potential 
application in the area of biomarker detection.[5] Despite being 
significantly smaller in size (typically 25 kDa) scFv 
recombinant antibodies retain the antigen specificity of their 
respective parent idiotypes. From an assay design perspective 
the resulting size reduction enables a significantly larger 
amount of the biological recognition element to be immobilised 
on a biosensor surface thereby reducing issues associated with 
non-specific binding and antibody surface orientation.[6] 
Moreover, recent developments in the fields of antibody 
libraries and expression bacteria have enabled recombinant 
antibodies to be engineered at lower cost and within a 
significantly shorter timeframe than those prepared in a living 
vertebrate host. Furthermore, recombinant antibodies such as 
scFv fragments contain peptide linkers between the VL and VH 
chains which can be easily functionalized to promote self-
assembly on Pt and Au electrode surfaces. To date however, the 
application of recombinant antibody technology to the field of 
bio-sensing and specifically biomarker detection remains to be 
fully exploited. The work herein documents a novel 
electrochemiluminescent biosensor for the detection of C-
Reactive protein. The potential advantages of combining 
  
recombinant antibody technology with existing highly sensitive 
electrochemiluminescent detection are made clear. The 
relevance of such technology to cardiac biomarker detection is 
demonstrated by utilising the cardiac biomarker C-Reactive 
protein as the target analyte.  
 
Electrochemiluminescent detection of C-Reactive protein  
 
CRP is an acute phase reactant in the inflammation response 
and one of a growing number of cardiac risk biomarkers that 
DUH XVHG WR GHWHUPLQH D SHUVRQ¶V ULVN RI GHYHORSLQJ FDUGLR-
vascular disease (CVD). While CRP is an indicator of 
inflammation, its presence at elevated levels is associated with 
an increased risk of stroke and myocardial infarction,[7] 
therefore, its accurate detection is of significant importance to 
clinicians and medical practitioners alike. Current clinical 
testing methods suffer from a relative lack of sensitivity with 
cut off limits of 3 - 5µg mL-1. High Sensitivity CRP (hs-CRP) 
ELISA-based testing kits with sensitivities of 3 pg mL-1 are 
now commercially available (Abcam). As previously stated the 
high sensitivity and low background signals of ECL biosensors 
are well documented[8, 9] and it was therefore anticipated that 
the incorporation of the significantly smaller yet highly specific 
scFv antibody fragments into an ECL-based cardiac biosensor 
would enhance detection limits due to (a) a higher 
concentration of capture antibody on the electrode surface (b) 
more capture antibodies having the correct surface orientation 
and (c) a reduction in non-specific binding due to the absence 
of a full length antibody. In addition, ECL-based systems offer 
the ability to tailor ECL probe materials for multiple analyte 
detection. A schematic of the developed assay can be seen in 
Scheme 1. Recombinant scFv antibodies with high affinity for 
monomeric C-Reactive Protein (mCRP KD - 3.53 x 10-10 
M)[10] were purified and were then immobilised on a Pt 
electrode surface followed by absorption and subsequent 
capture of pentameric CRP (pCRP) in solution during a 20 
minute timeframe. The high affinity of the scFv antibodies for 
C-Reactive protein ensured binding of both sizable and minute 
concentrations of the analyte protein to the electrode surface. 
The bound pCRP was then detected by ECL using the same 
recombinant scFv antibody fragment covalently labelled with 
the luminescent metal probe [Ru(bpy)2PICNH2]2+. Labeling of 
the luminescent metal probe was examined by spectroscopy, 
with solutions of labeled antibody producing absorption and 
emission profiles typical of the ruthenium metal probe 
(Supplementary data, Figure S1). The ECL assay procedure 
was carried out as previously described using tripropylamine 
(TPA) as a co-reactant. The electrocatalytic oxidation of TPA 
by ruthenium metal centres is a common mechanism which can 
result in the production of an ECL response when the oxidised 
co-reactant (TPA) and the oxidised ruthenium metal centre of 
the label react.[11, 12] Figure 1 shows the dependence of ECL 
emission over a CRP concentration range (5 fg mL-1 to 600 ng 
mL-1). The ECL emission observed at 1.2 V versus a 
silver/silver chloride (Ag/AgCl) reference electrode, 
corresponds with previous reports for a ruthenium metal centre 
and the shape of the curve is in accordance with ruthenium 
based ECL dynamics. The peak currents correspond to the 
electrocatalytic oxidation of TPA, (tri-n-propylamine) by the 
ruthenium label covalently attached to the anti-CRP scFv 
fragment. The absence of an ECL signal at 0.8 V illustrates that 
WKH (&/ PHFKDQLVP GRHV QRW LQYROYH WKH ³UHYLVLWHG URXWH´
where TPA radicals diffuse and react directly with [Ru(bpy)3]2+ 
to generate the excited state. The ECL signal observed at 1.2 V 
vs. Ag/AgCl is exclusive of the oxidation potential of TPA. 
 
  
Figure 1. Dependence of the ECL emission intensity on the 
CRP concentration.  From top to bottom at +1.2 V, the 
concentrations of CRP range from 600 ng mL-1 to 5 fg mL-1. 
Not all ECL responses are shown. The inset shows dependence 
of the logarithm of the maximum ECL intensity on log[CRP].  
The error bars are comparable to, or smaller than, the size of 
the symbols 
 
The distance between adjacent redox sites is a key factor governing 
the efficiency of the electron-transfer processes. It is equivalent to 
the charge diffusion in redox polymers involving an electron-
hopping process from site to site where transport of both electrons 
and charge compensating counter ions occurs simultaneously.[11, 
13] The rate of electron transfer k decays exponentially with the 
distance r between redox centres in the transition state. A 
bimolecular rate of electron transfer for Ru2+* to Ru3+ of ~106 M-1 s-1 
was reported previously, highlighting the fact that the excited state 
can be quenched efficiently by Ru3+ species in close proximity to the 
excited state Ru2+*.[13, 14] Although electron-hopping may be 
possible between adjacent ruthenium centres, given the extremely 
low levels of label present on the electrodes due to the low levels of 
antigen present, it is unlikely that the assay is affected by this 
phenomena.  ECL production, however, is highly dependent upon 
the rate of charge transfer (DCT). A fast rate of charge transfer 
ensures sufficient Ru3+ will be present to react with a given analyte 
and produce ECL. An insufficient amount of Ru3+ will result in 
decreased ECL emission and hence decreased sensitivity. The DCT 
value for the [Ru(bpy)2PICH2]2+ is typical of Ru2+/3+ systems, 
yielding a value of ~109 cm-1 s-1 consistent with previously published 
work. [10, 12-14] This value suggests that despite the minute 
concentrations of ruthenium label present, charge transfer via 
  
diffusion is not a limiting factor for the assay thereby further 
highlighting the suitability of ECL as a transduction mechanism for 
this assay. The voltammetric behavior of [Ru(bpy)2PICH2]2+ and the 
Randles-Sevçik plots are supplied in the supplementary material, 
Figure S2. 
 
A wide variety of hsCRP assays are currently available 
commercially with linear ranges from 0.1 mg to 10 mg /L, and 
as such are sufficiently sensitive to measure the vast majority of 
patients presenting at a clinic.  As such the bio-sensor herein 
was developed not as a replacement for such systems but to 
demonstrate the potential advantages of combining scFv 
antibody technology with ECL from the perspective of 
sensitivity, cost of production, response time and robustness. 
Figure 1 (inset), shows the dependence of the logarithm of the 
maximum ECL intensity on log[CRP] over a clinically 
significant range. The maximum value of 600 ng mL-1 
corresponds to 0.6 mg L-1, which is within the clinical range for 
low risk levels of CRP. Of significantly more interest is the 
lower limits of detection possible with this approach. The 
analytical sensitivity or limit of detection (LOD) was calculated 
using the formula [Average ECL emission of the blank + 3SD 
(blank)]. The LOD for the assay was calculated to be 0.3 fg mL-
1 considerably lower than the pg mL-1 detection limits of 
current commercially available CRP testing kits or the ng ml-1 
LODs obtained by electrochemical detection[14, 15]. The limit 
of quantification (LOQ) for the assay was calculated to be 
approximately 2 fg mL-1. While the clinical relevance of these 
figures may be limited to CRP concentrations typically 
occurring at pg mL-1 levels, if applied correctly the approach 
has the potential to improve current techniques for the 
monitoring of other myocardial infarction biomarkers such as 
Troponin T which are currently undetectable by conventional 
assays at sub 10 pg mL-1 concentrations. It is for applications 
such as this that the authors envisage the newly developed 
assay offers the most potential from a clinical perspective. 
While sensitivity is of immense importance in biosensor design, 
its significance is surpassed only by selectivity. While 
antibody/antigen interactions possess a high degree of 
specificity this is often negated by an inaccurate transduction 
process, often leading to the production of a false positive. To 
IXUWKHUYDOLGDWHWKHQHZVWUDWHJ\¶VXWLOLW\DQGVSecificity a series 
of controls were designed and analyzed experimentally. Figure 
2 shows the ECL response obtained for incomplete variants of 
the sandwich assay. The ECL signal circa 1.2 V was only 
observed when the complete sandwich assay was tested and 
indicates that a positive result is only observed in the presence 
of C-reactive protein. To assess variability parameters of the 
assay the results were performed using a sample size of n =3 on 
n=3 days. Figure 3 shows the averaged ECL response for 3 
separate assays conducted in three consecutive days. 
Figure 2. Dependence of the ECL emission intensity for modified 
film, without the scFv CRP antibody (red), without CRP antigen-
protein (blue), without labeled scFv CRP antibody (black) and with 
the complete sandwich assay (green). Inset shows a schematic of 
each of these controls. The CRP concentration used for the complete 
sandwich assay corresponds to 50 pg mL-1. 
In each case the CRP antigen concentration was 5 fg mL-1. Given the 
low quantity of analyte present some variability in the detection 
signal was expected, however, the associated standard deviation was 
calculated to be ~ 7 x 10-5 indicating excellent inter-electrode 
reproducibility. To assess the long term stability of the sensor ECL 
measurements were performed over 21 days (S3 supplementary 
material). During this timeframe an overall reduction in ECL 
intensity of 4.8% was recorded, corresponding favourably with 
previously reported stability data for Ru(bpy)32+ based ECL sensing 
platforms.[16, 17] As expected the ECL response time for the sensor 
excluding CRP incubation times varies with potential scan rate. A 
scan rate of 0.1 mVs-1 results in a response time of approximately 5-
6 seconds.  
 
Figure 3. The averaged ECL response for 3 different assays 
conducted over three consecutive days in presence of 5 fg mL-1 C-
Reactive protein.   
  
Previous work has shown that these scFv recombinant antibodies are 
extremely efficient at selectively discerning specific CRP antigens 
from other competing antigens.[18] Although not examined directly 
within this study, this previous work highlights the utility of this 
assay in selectively detecting CRP over the biological relevant 
concentration range. Due to the inherent nature of ECL no photonic 
excitation source is required thereby resulting in a significant cost 
saving and reduced background interference in comparison to UV 
and traditional fluorescent based detection systems. In addition, the 
lower costs associated with the production of recombinant antibodies 
compared to traditional antibody production methods involving 
vertebrate hosts ensure that the developed sensor is a promising 
platform for future point of care health monitoring.  
Conclusions 
In summary, this work highlights a proof-of-concept example 
for a new, robust and feasible ECL sensor for the determination 
of CRP with high sensitivity. We have combined recombinant 
antibody technology with ECL for the first time to produce a 
powerful assay for the determination of the cardiac biomarker 
C-Reactive protein at the fg level, which to our knowledge is 
the first reported sensor capable of detecting CRP at these 
detection levels. More importantly, this example paves the way 
for a broader application of recombinant antibody engineering 
across other biologically relevant biomarkers and we are 
currently pursuing this possibility.  The authors anticipate that 
in combining recombinant antibody engineering with low 
background detection techniques such as ECL, there exists 
much potential for the development of a new generation of 
sensitive, selective and rapid biosensor as well a significant 
scope for the improvement of existing systems, all with a 
common goal of improving point-of-care health monitoring. 
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